Covid-19 roundup: In­ovio nabs $3 mil­lion and a de­vel­op­ment part­ner for its vac­cine that's still on par­tial hold; Slaoui pro­pos­es halv­ing Mod­er­na vac­cine dos­es as dis­tri­b­u­tion lags

With its vac­cine can­di­date fi­nal­ly in Phase II, In­ovio is bag­ging $3 mil­lion in a part­ner­ship deal with Ad­vac­cine Bio­phar­ma­ceu­ti­cals Suzhou to de­vel­op and com­mer­cial­ize the can­di­date in Greater Chi­na.

Ad­vac­cine and In­ovio shook hands on a deal for ex­clu­sive rights to de­vel­op, man­u­fac­ture and com­mer­cial­ize the can­di­date, INO-4800, in Main­land Chi­na, Hong Kong, Macao and Tai­wan. In ad­di­tion to $3 mil­lion up­front, Ad­vac­cine is sweet­en­ing the deal with up to $108 mil­lion in mile­stone pay­ments. In re­turn, it stands to earn a “high sin­gle-dig­it per­cent­age” of an­nu­al net sales in each re­gion with­in Greater Chi­na. The com­pa­ny is al­so li­cens­ing its plas­mid man­u­fac­tur­ing process to In­ovio, with the right to sub­li­cense to In­ovio’s man­u­fac­tur­ing part­ners.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER